Hemogenyx Pharma Stock Price, News & Analysis

Hemogenyx Pharmaceuticals (LSE:HEMO) has filed an amendment to its ongoing Phase I clinical trial protocol for HG-CT-1, its CAR-T therapy for relapsed/refractory acute myeloid leukemia (R/R AML). The amendment seeks to expand trial eligibility to include children and adolescents, beyond the current adult patient population. This expansion aims to address a critical unmet medical need in pediatric oncology, particularly for R/R AML, which has limited treatment options and poor prognosis. The company has already treated two patients in the adult cohort of the trial.

Hemogenyx Pharmaceuticals (LSE:HEMO) has successfully raised £451,250 through a placing of 250,000 new ordinary shares at 180.5p per share. The shares were initially allotted to CEO Vladislav Sandler, who will direct their issue to an institution for immediate sale to an identified purchaser. The purchaser will receive one-for-one warrants exercisable for 36 months at 270 pence.

The funds will support the continuation of Phase I clinical trials for the company's HG-CT-1 therapy, targeting relapsed/refractory acute myeloid leukemia in adults. Two patients have already been infused with the treatment. Upon admission of the new shares, expected around May 14, 2025, the total number of issued shares will be 4,343,539.

Hemogenyx Pharmaceuticals (LSE: HEMO) has announced the successful treatment of a second patient in its Phase I clinical trial of HG-CT-1, a proprietary CAR-T cell therapy targeting relapsed or refractory acute myeloid leukemia (R/R AML) in adults. This milestone follows the successful first-in-human treatment, which showed a favorable initial safety profile with no adverse effects. The Phase I trial is designed as a dose-escalation study to evaluate HG-CT-1's safety profile and collect data on secondary endpoints including anti-leukemic activity, survival rates, and duration of response. The company aims to potentially expand into pediatric trials following successful initial outcomes, addressing a significant unmet medical need in childhood AML treatment.

Hemogenyx Pharmaceuticals (LSE: HEMO), a biopharmaceutical company focused on blood disease treatments, has released its final audited results for the year ending December 31, 2024. The company achieved several significant milestones including:

• Initiation of Phase I clinical trials for their HG-CT-1 product candidate
• Continued development of their Chimeric Bait Receptor antiviral/biodefence platform, which received recognition at major conferences
• Successful fundraising of £3.9 million through new ordinary shares in 2024
• Additional funding of £1.3 million secured in early 2025

The complete annual report is accessible on the company's website at hemogenyx.com.

Hemogenyx Pharmaceuticals (LSE:HEMO) has submitted its Annual Report to the FDA under the active Investigational New Drug (IND) application for HG-CT-1, their CAR-T cell therapy targeting relapsed or refractory acute myeloid leukemia (R/R AML).

The report covers the first year of clinical trials through February 6, 2025, and includes:

• Study information detailing trial design, objectives, and confirmation of first patient enrollment
• Quality data on HG-CT-1 drug product stability and lentiviral vector manufacturing
• Forward-looking plans for continued patient enrollment

The submission represents a significant milestone in HG-CT-1's clinical development, demonstrating the company's progress in advancing a potential therapy for R/R AML patients.

Hemogenyx Pharmaceuticals (LSE:HEMO), a clinical stage biopharmaceutical company focused on blood and autoimmune disease treatments, has announced its total voting rights as of March 31, 2025. The company's total issued share capital consists of 4,093,539 ordinary shares of 1p each, with none held in treasury.

This figure serves as the denominator for shareholders calculating their notification requirements under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The company operates through its US subsidiaries in New York City, where it maintains a state-of-the-art research facility developing several distinct product candidates and platform technologies.

Hemogenyx Pharmaceuticals (LSE: HEMO) has announced successful initial safety results for the first patient treated in its Phase I clinical trial of HG-CT-1, a proprietary CAR-T cell therapy targeting relapsed or refractory acute myeloid leukemia (R/R AML) in adults.

The treatment demonstrated favorable tolerability with no adverse effects, meeting the primary safety assessment criteria. Early efficacy signs are reported as encouraging, with ongoing patient monitoring to evaluate secondary endpoints including:

• AML-specific response criteria assessment
• Overall survival evaluation
• Progression-free survival measurement
• Duration of response determination

The company is currently manufacturing HG-CT-1 for a second patient as part of this dose-escalation study, which aims to evaluate the therapy's potential in treating one of the most challenging forms of leukemia.

Hemogenyx Pharmaceuticals (LSE:HEMO) has announced the recruitment of its second patient for the clinical trial of HG-CT-1, their proprietary CAR-T cell therapy. The trial focuses on treating relapsed or refractory acute myeloid leukemia (R/R AML) in adult patients.

The company's scientific team will soon begin manufacturing HG-CT-1 for the second patient. This development represents a significant milestone in advancing a potential breakthrough treatment for AML patients with therapeutic options.

The recruitment progress suggests promising initial trial results, demonstrating the company's commitment to addressing urgent unmet medical needs in blood disease treatment.